Evidence map›Paper›PMID 42338396›Full record

Observational studyClinical pharmacology and therapeutics2026

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

Jérémie Tachet, Sara C Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy-Hulliger, Jörg P Halter, Jakob R Passweg, David Haefliger, Carine Bardinet, Laurent A Decosterd and 2 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jérémie TachetService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2442-6327
Sara C MeyerDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID 0000-0002-0308-185X
Francesco GrandoniService and Central Laboratory of Hematology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-2208-2070
Emmanuel HaefligerDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID 0000-0003-2426-2366
Monika Nagy-HulligerService of Hematology, Hospital of Morges, Morges, Switzerland.ORCID 0000-0003-3609-4523
Jörg P HalterDivision of Hematology, Basel University Hospital and University of Basel, Basel, Switzerland.ORCID 0000-0003-4304-1956
Jakob R PasswegDivision of Hematology, Basel University Hospital and University of Basel, Basel, Switzerland.ORCID 0000-0001-7092-3351
David HaefligerService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7896-0894
Carine BardinetLaboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Laurent A DecosterdLaboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9840-1325
Monia GuidiService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6419-9317
François R GirardinService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0842-927X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real-world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure-response relationships to assess the potential role of therapeutic drug monitoring. In total, 221 steady-state ruxolitinib concentrations from 77 adult patients enrolled across several centers in Switzerland were analyzed. Demographic and clinical data were recorded at each visit. Population pharmacokinetic (popPK) analysis was performed with MonolixSuite® 2024R1 (Lixoft, France). Model-based simulations were used to predict trough concentration (C

Indexed as

Hematologic NeoplasmsPyrazolesAdultAgedAged, 80 and overArea Under CurveCytochrome P-450 CYP2C9Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDose-Response Relationship, DrugDrug InteractionsDrug MonitoringFemaleHumansMaleMiddle AgedCYP2C9 protein, humanCYP3A4 protein, humanCytochrome P-450 CYP2C9Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID42338396
PMCPMC13339044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.